GoodRx Receives Overweight Rating and Higher Price Target from Wells Fargo Analysts

Monday, 25 March 2024, 20:24

GoodRx's stock surged 7.5% after an upgrade to 'overweight' from Wall Street analysts at Wells Fargo, who raised the price target to $10. The positive outlook is driven by expectations of improved performance, revenue visibility, and beating consensus estimates. GoodRx's recent financial report showed growth in revenue and active customers, signaling a potential turnaround for the health-tech stock.
https://store.livarava.com/43a7b98b-eae6-11ee-aeb4-63fd8ea994ba.jpg
GoodRx Receives Overweight Rating and Higher Price Target from Wells Fargo Analysts

Reasons Behind GoodRx's Surge Today

The prescription-drug upstart, GoodRx (NASDAQ: GDRX), experienced a 7.5% rally after receiving an upgrade from analysts at Wells Fargo.

Upgrade Details

  • Wells Fargo raised the rating from 'equal weight' to 'overweight.'
  • The price target was increased from $7.50 to $10.

Positive Outlook: Analysts expect GoodRx to outperform its peers and close the valuation gap, setting up for significant growth in the upcoming months.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe